Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review

Progression-Free Survival as Early Efficacy Endpoint in Resectable Esophageal Cancer Treated With Neoadjuvant Therapy: A Systematic Review

To investigate literature-based evidence regarding progression-free survival (PFS) as an early efficacy endpoint in patients with resectable esophageal or gastroesophageal junction (GEJ) cancer receiving neoadjuvant therapy, this study identified large-scale randomized controlled trials (RCTs) with...

Full description

Bibliographic Details
Main Authors: Jie Zhu, Jin Tao, Zhen Dai, Yan Tan, Li Jiang, Qifeng Wang, Jinyi Lang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
esophageal cancer
neoadjuvant therapy
progression-free survival
early efficacy endpoint
surrogate endpoint
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.771546/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.771546/full

Similar Items